Algert Global LLC Acquires 62,277 Shares of Insulet Corporation $PODD

Algert Global LLC boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 75.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 144,584 shares of the medical instruments supplier's stock after acquiring an additional 62,277 shares during the quarter. Algert Global LLC owned 0.21% of Insulet worth $22,013,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PODD. Mitsubishi UFJ Trust & Banking Corp grew its stake in Insulet by 26.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier's stock worth $12,484,000 after purchasing an additional 9,206 shares in the last quarter. OP Asset Management Ltd bought a new stake in Insulet during the 1st quarter valued at $1,513,000. OneDigital Investment Advisors LLC bought a new stake in Insulet during the 2nd quarter valued at $6,741,000. Strs Ohio lifted its holdings in shares of Insulet by 36.0% in the 4th quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier's stock worth $6,447,000 after buying an additional 6,003 shares during the period. Finally, SEB Asset Management AB purchased a new stake in shares of Insulet in the 1st quarter worth $24,700,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
• Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Analysts Set New Price Targets

PODD has been the topic of several research reports. Piper Sandler cut their price target on Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. UBS Group lowered their price objective on shares of Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a research note on Thursday, August 6th. The Goldman Sachs Group reiterated a "buy" rating and set a $205.00 target price on shares of Insulet in a report on Wednesday, May 27th. Weiss Ratings downgraded shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, June 24th. Finally, Sanford C. Bernstein reduced their price target on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $195.40.

Insulet Stock Performance

Shares of PODD stock opened at $145.42 on Tuesday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The business's fifty day simple moving average is $154.61 and its 200-day simple moving average is $183.56. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.08 billion, a PE ratio of 27.18, a PEG ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the business earned $1.17 EPS. The firm's revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.36% of the company's stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source